Roche’s antiviral medication, Xofluza (baloxavir marboxil), has successfully met its primary endpoint in the phase III CENTERSTONE study. The findings revealed that a single oral dose of Xofluza significantly diminished the risk of influenza transmission within households. Additionally, Xofluza was well tolerated, with no new safety concerns identified.Notably, the CENTERSTONE study is the first global phase III trial to demonstrate a transmission reduction benefit associated with an antiviral used for a respiratory viral illness. This new data could enhance the profile of Xofluza, which is already approved for treating influenza symptoms and preventing infection post-exposure.The material has been provided by InstaForex Company – www.instaforex.com
- Czech Retail Sales Growth Accelerates in August, Reaching 5.30% - October 8, 2024
- Czech Unemployment Rate Sees Slight Uptick in September - October 8, 2024
- France Sees Rise in Imports: August Figures Show a Notable Increase - October 8, 2024
